{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:story:071ebfe4-53ad-4225-be3b-54b7848fd287", "type": "composite", "version": "1", "versioncreated": "2026-11-14T04:15:23.656844Z", "firstcreated": "2026-11-14T04:15:23.656844Z", "pubstatus": "usable", "language": "uk", "headline": "Mangoceuticals змінила умови привілейованих акцій і створила новий клас Series D", "description_text": "Телемедичний сервіс із лікування випадіння волосся у чоловіків оновив структуру свого капіталу: змінено умови чинних привілейованих акцій і запроваджено новий клас Series D.", "associations": {"item-0": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:01f9aef7-2d10-4f89-9994-1a22b84cedd4", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-11-14T04:15:39.958146Z", "firstcreated": "2026-11-14T04:15:23.656844Z", "pubstatus": "usable", "urgency": 5, "language": "uk", "headline": "Mangoceuticals змінила умови привілейованих акцій і створила новий клас Series D", "byline": "Євген Величко", "located": "Ukraine", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Карторг", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Карторг”. Set rel=canonical to https://cartorg.com.ua/kompanii/mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d/ when publishing on the web.", "description_text": "Телемедичний сервіс із лікування випадіння волосся у чоловіків оновив структуру свого капіталу: змінено умови чинних привілейованих акцій і запроваджено новий клас Series D.", "altids": {"mosaic": "01f9aef7-2d10-4f89-9994-1a22b84cedd4", "story": "071ebfe4-53ad-4225-be3b-54b7848fd287", "slug": "mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d"}, "subject": [{"name": "Economy and business", "rel": "direct", "literal": "economy", "code": "medtop:04000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/04000000"}], "place": [{"name": "Ukraine", "literal": "ua", "code": "UA", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:40e25018-83b7-42e1-8b58-a2eff8eb3b3c", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push", "description_text": "Mirum Pharmaceuticals pushes rare-disease strategy at Cantor healthcare conference", "copyrightholder": "commons.wikimedia.org", "copyrightnotice": "commons.wikimedia.org", "usageterms": "Open licence: the credit line must travel with the file.", "altids": {"wireva": "40e25018-83b7-42e1-8b58-a2eff8eb3b3c"}, "extra": {"wireva:delivery_mode": "file", "wireva:rights": {"licence": "CC BY 4.0", "licence_url": "https://creativecommons.org/licenses/by/4.0/", "licence_raw": "CC BY 4.0", "licence_verified_at": "2026-11-14T04:15:39.975416Z", "attribution_required": true, "attribution_text": "commons.wikimedia.org", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "commons.wikimedia.org", "source_url": "https://commons.wikimedia.org/wiki/File:Allen_%26_Hanbury,General_Pharmaceutical_Laboratory_Wellcome_L0005119.jpg", "source_page_url": "https://commons.wikimedia.org/wiki/File:Allen_%26_Hanbury,General_Pharmaceutical_Laboratory_Wellcome_L0005119.jpg", "our_page_url": "https://cartorg.com.ua/kompanii/mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d/"}, "wireva:role": "lead"}, "renditions": {"original": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/fcdd91ea7b72b032b45ae65aa54a0c0e979160a3a3b61e93e29aa4d95cc7241b.jpg", "mimetype": "image/jpeg", "width": 1175, "height": 900, "sizeinbytes": 482851}, "source": {"href": "https://commons.wikimedia.org/wiki/File:Allen_%26_Hanbury,General_Pharmaceutical_Laboratory_Wellcome_L0005119.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:071ebfe4-53ad-4225-be3b-54b7848fd287", "slug": "mangoceuticals-series-d-20261114", "status": "developing", "languages": ["uk"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "agency_original", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Карторг", "canonical_required": true, "canonical_url": "https://cartorg.com.ua/kompanii/mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "agency_original_unassessed_allow", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Матеріал підготовлено за допомогою ШІ під редакційною відповідальністю Haydamax OÜ.", "independence_check": {"status": "not_assessed", "score": 0.0, "checked_at": "2026-11-14T04:15:39.972061Z"}, "sources": [{"url": "https://www.investing.com/news/sec-filings/mangoceuticals-amends-preferred-stock-terms-and-establishes-new-series-d-shares-93CH-5026709", "title": "Mangoceuticals amends preferred stock terms and establishes new Series D shares", "publisher": "investing.com", "type": "rss", "role": "primary", "official": false, "retrieved_at": "2026-11-14T04:15:39.962866Z", "published_at": "2026-11-13T21:44:46Z"}]}, "wireva:publication": {"name": "Карторг", "domain": "cartorg.com.ua", "country": "UA", "url": "https://cartorg.com.ua/kompanii/mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/01f9aef7-2d10-4f89-9994-1a22b84cedd4", "html": "https://wireva.mib.news/item/01f9aef7-2d10-4f89-9994-1a22b84cedd4/mangoceuticals-zminila-umovi-privileiovanikh-aktsii-i-stvorila-novii-klas-series-d/", "story": "https://wireva.mib.news/story/mangoceuticals-series-d-20261114/"}, "wireva:metrics": {"word_count": 333, "char_count": 2425, "reading_time_seconds": 173}}}}, "extra": {"wireva:languages": ["uk"], "wireva:status": "developing", "wireva:item_count": 1}}